{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:55:03Z","timestamp":1776318903602,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BLCA) is clinically heterogeneous, and conventional staging does not fully capture individual risk. Ribosome biogenesis (RiBi) is implicated in cancer, but its prognostic relevance in BLCA is not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Survival-annotated tumor transcriptomes from TCGA-BLCA were analyzed and externally evaluated in GSE13507. Tumor-normal differential expression was intersected with a curated RiBi gene set to prioritize candidates. Cox modeling with machine-learning\u2013based strategy selection yielded a three-gene ribosome biogenesis\u2013related score (RBscore). RBscore was evaluated for overall survival (OS) stratification, independence from clinicopathological variables, and integration with nodal status in a nomogram. Pathway enrichment, immune features, pharmacogenomic associations supported by molecular docking, and somatic mutation and transcription factor (TF) network features were examined. Signature gene expression was assessed in bladder cancer cell lines and paired clinical tissues. PRKDC protein expression was further evaluated by immunohistochemistry (IHC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PIN4, POP4, and PRKDC comprised RBscore, which stratified OS in TCGA-BLCA and remained prognostic in GSE13507. High RBscore tumors were enriched for antigen processing and presentation and ribosome-related programs, and RBscore groups differed in immune contexture. PRKDC expression correlated with immune checkpoint-related genes including CD274, TNFRSF14, and TNFRSF25. Pharmacogenomic analyses nominated candidate compounds, with docking supporting putative binding. TP53 mutations were more frequent in the high-RBscore group. RBscore genes showed tumor-associated dysregulation in cells and tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RBscore captures prognostic heterogeneity in BLCA and connects RiBi-associated transcriptional programs with pathway activity, immune contexture, and complementary pharmacogenomic and genomic features, providing a basis for integrative risk assessment and testable hypotheses for downstream validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1810132","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:04Z","timestamp":1776317104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ribosome biogenesis programs define a three-gene RBscore with prognostic relevance in bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Guangyue","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supeng","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lexing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Institute of Urology, Anhui Medical University","place":["Hefei, Anhui, China"]},{"name":"Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"Bmj"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: A narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000004452","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2139\/ssrn.3372965","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.sbi.2020.09.003","article-title":"Structural overview of macromolecular machines involved in ribosome biogenesis","volume":"67","author":"Frazier","year":"2020","journal-title":"Curr Opin Struct Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","article-title":"Ribosome biogenesis in disease: New players and therapeutic targets","volume":"8","author":"Jiao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1038\/s41467-023-42257-8","article-title":"USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and cancer cell survival upon ribotoxic stress","volume":"14","author":"Qin","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-024-01526-9","article-title":"METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation","volume":"17","author":"Xue","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","article-title":"Ribosomal proteins and human diseases: Molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1602898","article-title":"Multi-omics analysis reveals the role of ribosome biogenesis in Malignant clear cell renal cell carcinoma and the development of a machine learning-based prognostic model","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00999-w","article-title":"p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways","volume":"29","author":"Lindstr\u00f6m","year":"2022","journal-title":"Cell Death Differ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae023","article-title":"Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer","volume":"25","author":"Zang","year":"2024","journal-title":"Brief Bioinform"},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: New players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2003.08.007","article-title":"The enigma of ribonuclease P evolution","volume":"19","author":"Hartmann","year":"2003","journal-title":"Trends Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc0149","article-title":"Structural insight into precursor ribosomal RNA processing by ribonuclease MRP","volume":"369","author":"Lan","year":"2020","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.m900147-mcp200","article-title":"Parvulin (Par14), a peptidyl-prolyl cis-trans isomerase, is a novel rRNA processing factor that evolved in the metazoan lineage","volume":"8","author":"Fujiyama-Nakamura","year":"2009","journal-title":"Mol Cell Proteomics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.921653","article-title":"PIN1 and PIN4 inhibition via parvulin impeders Juglone, PiB, ATRA, 6,7,4'-THIF, KPT6566, and EGCG thwarted hepatitis B virus replication","volume":"14","author":"Saeed","year":"2023","journal-title":"Front Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2934","article-title":"DNA-dependent protein kinase specifically represses promoter-directed transcription initiation by RNA polymerase I","volume":"92","author":"Labhart","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae316","article-title":"DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair","volume":"52","author":"Li","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13046-024-03131-7","article-title":"Inhibiting interferon-\u03b3 induced cancer intrinsic TNFRSF14 elevation restrains the Malignant progression of glioblastoma","volume":"43","author":"Han","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008810","article-title":"Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth","volume":"12","author":"Lyu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-023-01883-y","article-title":"Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375\/PRKDC axis and PD-L1 phosphorylation","volume":"22","author":"Miao","year":"2023","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational processes shape the landscape of TP53 mutations in human cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: Direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0402","article-title":"Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.10.013","article-title":"Extracellular matrix component signaling in cancer","volume":"97","author":"Multhaupt","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-2613","article-title":"Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis","volume":"84","author":"Waters","year":"2024","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00747.x","article-title":"Association of nucleophosmin\/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples","volume":"29","author":"Tsui","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14835","article-title":"Importance of PNO1 for growth and survival of urinary bladder carcinoma: Role in core-regulatory circuitry","volume":"24","author":"Lin","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.895413","article-title":"Predictive value of the log odds of negative lymph nodes\/T stage as a novel prognostic factor in bladder cancer patients after radical cystectomy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.015","article-title":"Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology","volume":"42","author":"Saddawi-Konefka","year":"2024","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.04.008","article-title":"Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy","volume":"11","author":"von Renesse","year":"2025","journal-title":"Trends Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-023-00853-6","article-title":"BLCA prognostic model creation and validation based on immune gene-metabolic gene combination","volume":"14","author":"Yue","year":"2023","journal-title":"Discov Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7150\/jca.38741","article-title":"Construction and validation of an eight-gene signature with great prognostic value in bladder cancer","volume":"11","author":"Yan","year":"2020","journal-title":"J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: A prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq734","article-title":"A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906301","article-title":"Rediscovery of traditional plant medicine: An underestimated anticancer drug of chelerythrine","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:05Z","timestamp":1776317105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1810132"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1810132","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1810132"}}